



## Uni-Bio Science Group Ltd. 聯康生物科技集團有限公司\*

### Uni-Bio Science Group Garneres “Pharmaceuticals Award” for Best Innovation at Hong Kong Business Listed Companies Awards

(Hong Kong, 16 July 2015) – **Uni-Bio Science Group Limited** (“Uni-Bio” or the “Group”; HKEx code: 690) has garnered the “Pharmaceuticals Award” for Best Innovation with its Uni-E4 project at the inaugural Hong Kong Business (“HKB”) Listed Companies Awards. As the winner under the pharmaceuticals category, the accolade is a strong testimony for the innovation of Uni-Bio’s Uni-E4, the Group’s proprietary recombinant GLP-1 receptor agonist for the treatment of Type-2 diabetes.

**Mr. Kingsley Leung, Executive Director of Uni-Bio Science Group**, said, *“Competing alongside industry peers, we are delighted to be chosen as the winner in the pharmaceuticals category at the HKB Listed Companies Awards. This accolade acknowledges 10 years of hard work by our highly-skilled R&D team in developing Uni-E4. Compared to existing products, Uni-E4 offers a cost-effective alternative to manage diabetes and associated complications – it can effectively reduce blood sugar levels without the increased risk of hypoglycemia, and provide other collateral benefits, such as weight loss and stimulating beta cell regeneration. Therefore, Uni-E4 offers patients, especially overweight diabetics, with a long-term solution for managing their illness. These innovations were instrumental in Uni-Bio garnering this prestigious award. In the future, we will continue fulfilling our commitment to identify and develop new and more efficacious treatment options for our targeted patients in order to better treat their illnesses.”*

- End -

#### **Photo caption**

**Mr. Kingsley Leung, Executive Director of Uni-Bio**, accepts the trophy for the Pharmaceuticals Award for Best Innovation on behalf of the Group from Mr. Tim Charlton, Editor-in-Chief of *Hong Kong Business*.



**About Uni-Bio Science Group Limited (SEHK: 0690)**

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. Both operations in Beijing and Shenzhen produce and distribute their own pharmaceutical products. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology

**About Hong Kong Business Listed Companies Awards**

Organized by *Hong Kong Business*, The Hong Kong Business Listed Companies Awards recognises the listed companies in Hong Kong best able to differentiate themselves within their respective industry through innovative and outstanding projects. The awards encompass a wide array of 81 industry categories from aerospace to venture capital. Criteria included uniqueness and innovation, effectiveness and dynamism, and the most innovative projects and best practices which significantly enhanced the company's business in Hong Kong and China have been selected by the judging committee for the awards.

**Media Enquiries:**

***Strategic Financial Relations Limited***

Veron Ng           Phone: +852 2864 4831  
Angelus Lau       Phone: +852 2864 4805  
Caley Chan        Phone: +852 2114 4950  
                      Fax:    +852 2527 1196

Email: veron.ng@sprg.com.hk  
Email: angelus.lau@sprg.com.hk  
Email: caley.chan@sprg.com.hk